Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 IRX Therapeutics Enters Research Collaboration
 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

IRX Therapeutics Enters Research Collaboration


IRX Therapeutics has signed a research collaboration agreement with a leading research-based pharmaceutical company to assess the potential effects of IRX-2 on the tumor microenvironment.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

IRX Therapeutics has signed a research collaboration agreement with a leading research-based pharmaceutical company to assess the potential effects of IRX-2 on the tumor microenvironment. Tumor specimens from subjects treated with IRX-2 and control subjects will be analyzed using gene analysis technology to characterize the action of IRX-2 immunotherapy at the molecular level.

IRX-2 is designed to broadly restore the immune system to overcome cancer–induced immune suppression and restore anti-tumor response. The IRX-2 immunomodulator includes multiple cytokine components that work to activate different arms of the immune system. IRX Therapeutics performed a Phase II trial that enrolled patients with newly diagnosed head and neck squamous cell cancer who received IRX-2 immunotherapy prior to surgery.

“This is a great opportunity for IRX Therapeutics to work with one of the leading developers of cancer therapies to further our understanding of the action of our novel immunomodulator, IRX-2. We are hopeful that these studies will further evidence the potential of IRX-2 to effect an immune based attack on a cancer patient’s tumor,” said John W. Hadden II, president and chief executive officer of IRX Therapeutics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters